• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Abivax

< Previous 1 2 Next >
News headline image
Abivax Provides 2026 Corporate Outlook
January 07, 2026
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax to be Added to Nasdaq Biotechnology Index
December 18, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
December 17, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Presents Third Quarter 2025 Financial Results
December 15, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
November 03, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
October 06, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
October 05, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
September 23, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
September 12, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Presents First Half 2025 Financial Results
September 08, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Closing of $747.5 Million Public Offering
July 28, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
July 25, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
July 24, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 24, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 24, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Launch of Public Offering
July 23, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
July 22, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Results of its June 6, 2025 Annual General Meeting
June 11, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Presents First Quarter 2025 Financial Results
June 02, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
April 29, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
April 22, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
April 22, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
March 26, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Full Year 2024 Financial Results
March 24, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
February 21, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Publishes 2025 Financial Calendar
January 28, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
January 23, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
January 09, 2025
From Abivax
Via GlobeNewswire
Tickers ABVX
News headline image
Abivax Announces a Change to the Composition of its Board of Directors
December 23, 2024
From Abivax
Via GlobeNewswire
Tickers ABVX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap